Standard BioTools Inc (NASDAQ: LAB) kicked off on Monday, down -7.04% from the previous trading day, before settling in for the closing price of $1.42. Over the past 52 weeks, LAB has traded in a range of $0.92-$2.32.
During the last 5-year period, the sales growth of Healthcare Sector giant was 11.61%. While this was happening, its average annual earnings per share was recorded 66.03%. With a float of $365.52 million, this company’s outstanding shares have now reached $381.69 million.
Standard BioTools Inc (LAB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 4.31%, while institutional ownership is 74.17%. The most recent insider transaction that took place on Sep 09 ’25, was worth 128,920. In this transaction Director of this company bought 100,000 shares at a rate of $1.29, taking the stock ownership to the 60,875,000 shares. Before that another transaction happened on Sep 04 ’25, when Company’s Director bought 250,000 for $1.28, making the entire transaction worth $319,350. This insider now owns 60,775,000 shares in total.
Standard BioTools Inc (LAB) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.03 earnings per share (EPS), higher than consensus estimate (set at -0.08) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Take a look at Standard BioTools Inc’s (LAB) current performance indicators. Last quarter, stock had a quick ratio of 4.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.32, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Looking closely at Standard BioTools Inc (NASDAQ: LAB), its last 5-days average volume was 1.39 million, which is a drop from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 53.97%.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 55.42%, which indicates a significant increase from 28.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0864 in the past 14 days, which was higher than the 0.0800 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3100, while its 200-day Moving Average is $1.2650. However, in the short run, Standard BioTools Inc’s stock first resistance to watch stands at $1.4033. Second resistance stands at $1.4867. The third major resistance level sits at $1.5433. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.2067. Now, if the price goes above the second support level, the third support stands at $1.1233.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
The company with the Market Capitalisation of 504.23 million has total of 381,995K Shares Outstanding. Its annual sales at the moment are 174,430 K in contrast with the sum of -138,890 K annual income. Company’s last quarter sales were recorded 21,760 K and last quarter income was -33,460 K.
